NCT Number: NCT05050084
Phase: Phase 3
Trial Summary: This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Acronym:
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives